Skyline Therapeutics

Skyline Therapeutics is a fully integrated gene and cell therapy company dedicated to the discovery, development and delivery of innovative therapies. Through the development of transformative therapies, we are committed to making a meaningful impact on the lives of patients with devastating diseases. Led by a world-class team of experts and leaders in science, technology and business who brings to Skyline industry-leading know-how, we have established a proprietary AAV gene therapy platform that integrates novel capsid engineering and vector design, analytical and process development, and state-of-the-art GMP manufacturing capabilities that support large scale clinical-grade vector production. Based on our robust end-to-end AAV-based platform, we are rapidly advancing a pipeline of diversified programs to address multiple serious diseases that could be altered through a disruptive gene and cell therapy approach. Founded in 2019, Skyline Therapeutics is headquartered in China, with well-established research, development and manufacturing capabilities in Shanghai and Hangzhou.